

REMARKS

This amendment was made to correct a reference made to U.S. Patent 6,651,982 in the specification. The reference is to U.S. Patent 5,651,982.

This amendment was not made for matters affecting patentability. No new subject matter has been incorporated into the application as a result of this amendment.

Attached hereto is a marked-up version of the change made to the specification by the current amendment.


Entry of the above amendment is respectfully requested prior to the examination of this application.

Favorable consideration and an early action on the merits is respectfully requested.

The Examiner is hereby authorized to charge any additional fees associated with this submission to our Deposit Account No. 04-0100.

Respectfully submitted,

Dated: September 13, 2002



Michael J. Sweedler
Reg. No. 19,937
Attorney for Applicant(s)

DARBY & DARBY, P.C.
Post Office Box 5257
New York, NY 10150-5257
Phone (212) 527-7700



Customer No.:



07278

PATENT TRADEMARK OFFICE

Docket No: 3671/OK437

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Armin PRASCH and Bernhard LUY

Serial No: 10/089,663

Filed: March 29, 2002

For: BIODEGRADABLE EXCIPIENT SYSTEMS FOR THERAPEUTICALLY
ACTIVE SUBSTANCES AND METHOD FOR PRODUCING SAME

MARK-UP VERSION OF PRELIMINARY AMENDMENT

Hon. Commissioner of
Patents and Trademarks
Washington, DC 20231

Sir:

Prior to examination, please amend the above-identified application pursuant
to 37 C.F.R. §1.121 as follows:

IN THE SPECIFICATION:

Please replace the paragraph beginning at page 3, line 38 with the following rewritten paragraph:

-- A number of publications have disclosed fibrin glues as carriers of active ingredients. Besides the use of antibiotics for suppressing local infections, there have also been addition of cytostatics to fibrin glues for local chemotherapeutic treatment for example of remaining cancer cells after surgical removal of the primary tumor. Zinc, for example, has also been incorporated into fibrin glues in order thus to achieve a higher content of zinc over a prolonged period directly in the wound and thus make improved wound healing possible (US [6,651,982] 5,651,982). In addition, EP 804153A1 also describes the combination of a fibrin glue with a therapeutic active ingredient which can be employed, for example, after surgical removal of a tumor, as radiotherapeutic active ingredient. --